LTLuiza Sarmento Tatagiba

Luiza Sarmento Tatagiba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luiza Sarmento Tatagiba has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluating sotatercept in the treatment of pulmonary arterial hypertension

    by William Salibe-Filho, Nathalia Zorze Rossetto, Luiza Sarmento Tatagiba, Yuri de Deus MontAlverne Parente, Carlos Viana Poyares Jardim, Caio Julio Cesar Fernandes, José Leonidas Alves-Junior, Rogerio Souza

    Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling, right ventricular overload, and premature death. Despite advances achieved through endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogs, these agents primarily act as vasodilators and do not reverse underlying vascular pathology. Sotatercept, a first-in-class activin signaling modulator, restores the balance between pro- and antiproliferative signaling within the pulmonary vasculature via the TGF-β/activin-BMPR2 pathway, offering a novel disease-modifying mechanism. Following encouraging preclinical data, a series of clinical trials, PULSAR, SPECTRA, STELLAR, ZENITH, and HYPERION, demonstrated consistent efficacy across diverse PAH populations. Sotatercept significantly reduced pulmonary vascular resistance, improved exercise capacity, and decreased morbidity and mortality, including in patients receiving maximal background therapy. Across studies, adverse events were generally mild to moderate, with epistaxis, telangiectasia, and increased hemoglobin being the most common treatment-related events. Collectively, these findings establish sotatercept as a major advance in PAH therapy, marking a transition from purely vasodilatory approaches toward targeted modulation of vascular remodeling. By improving pulmonary hemodynamics and right ventricular function, sotatercept represents a new therapeutic option for improving clinical outcomes across different stages of PAH.


  • Open Access

    Upfront combination therapy with sildenafil and ambrisentan in patients with chronic thromboembolic pulmonary hypertension

    by William Salibe-Filho1, Tulio Martins Vieira1, José Leonidas Alves-Junior1, Yally Priscila Pessôa Nascimento1, Luiza Sarmento Tatagiba1, Caio Julio Cesar Fernandes1, Carlos Viana Poyares Jardim1, Mario Terra-Filho1, Rogerio Souza1

    Objective: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism, being characterized by persistent obstruction of pulmonary vessels and leading to increased pulmonary vascular resistance and right ventricular failure. Although pulmonary endarterectomy is the preferred treatment, medical therapies may offer clinical benefits in specific settings. We sought to evaluate the clinical and hemodynamic response of CTEPH patients treated with sildenafil and ambrisentan upfront combination therapy. Methods: This was a retrospective cohort study including patients with operable and inoperable CTEPH. The patients were followed from 2019 to 2022 and were treated with sildenafil and ambrisentan as first-line therapy. Results: Functional and hemodynamic data were analyzed at baseline and after a minimum of six months of therapy. Following treatment, there was a notable improvement in functional class, natriuretic peptide levels, and invasive hemodynamics. Conclusions: The combined use of sildenafil and ambrisentan appears to be associated with clinical, functional, and hemodynamic improvement in patients with CTEPH.